Lyra Therapeutics, Inc. (NASDAQ:LYRA – Get Rating) dropped 4.8% during mid-day trading on Friday . The company traded as low as $2.69 and last traded at $2.75. Approximately 65,246 shares were traded during mid-day trading, an increase of 86% from the average daily volume of 35,119 shares. The stock had previously closed at $2.89.
Lyra Therapeutics Stock Down 4.8 %
The company has a market capitalization of $87.52 million, a price-to-earnings ratio of -1.14 and a beta of -0.42. The stock’s fifty day moving average price is $3.18 and its 200-day moving average price is $4.71.
Lyra Therapeutics (NASDAQ:LYRA – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.02. Lyra Therapeutics had a negative net margin of 778.87% and a negative return on equity of 77.62%. The company had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.41 million. Analysts anticipate that Lyra Therapeutics, Inc. will post -1.81 EPS for the current year.
Hedge Funds Weigh In On Lyra Therapeutics
About Lyra Therapeutics
Lyra Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
- Get a free copy of the StockNews.com research report on Lyra Therapeutics (LYRA)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.